Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Tzield Coverage Policy | OpenPayer
    Ask Trek AI about this page
    Draftblue cross blue shield - tennesseePolicy ID_CHS_56782026_1026

    Teplizumab-mzwv (Tzield) Coverage Policy

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_56782026_1026 alerts

    Get alerted when Policy ID_CHS_56782026_1026 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity criteria for Tzield to delay the onset of Stage 3 type 1 diabetes or delay decline in endogenous insulin production in recently diagnosed Stage 3 type 1 diabetes, subject to specified clinical, age, prescriber, documentation, and treatment-course requirements.

    Policy Summary
    Payerblue cross blue shield - tennessee
    PolicyTeplizumab-mzwv (Tzield) Coverage Policy
    Policy CodePolicy ID_CHS_56782026_1026
    Change TypeNo material clinical or coverage changes
    Effective DateDecember 31, 2026
    Next Review DateN/A
    Key ActionSubmit indication-specific clinical documentation and ensure Tzield is prescribed by or in consultation with an endocrinologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered FDA-approved indications
    1 monthStage 2 authorization
    12 monthsStage 3 authorization
    14 daysStage 2 treatment course

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 courses
    Maximum Stage 3 courses
    45 yearsStage 2 upper age threshold

    Covered Indications and Policy Limits

    Delay of Stage 3 Type 1 Diabetes

    Authorization of 1 month may be granted when all criteria are met.

    Stage 2 type 1 diabetes criteria

    • Age: Member is 1 to less than 45 years of age.1 to less than 45 years
    • Autoantibodies: Member is positive for two or more pancreatic islet cell autoantibodies on two separate occasions.At least 2 on 2 separate occasions

      Eligible antibodies include GAD, IAA, IA-2A, ZnT8A, and ICA.

    • Dysglycemia

      • Fasting glucose: Fasting blood glucose is 100 to 125 mg/dL (5.6 to 6.9 mmol/L).100 to 125 mg/dL
      • Postprandial glucose: Two-hour postprandial plasma glucose is at least 140 mg/dL and less than 200 mg/dL (7.8 to 11.1 mmol/L).At least 140 and less than 200 mg/dL
      • A1C is at least 5.7% and less than 6.5% (39-47 mmol/mol), or has increased by at least 10%.At least 5.7% and less than 6.5%, or at least 10% increase
    • Clinical status: Member does not have symptoms associated with type 1 diabetes and does not have type 2 diabetes or another form of diabetes, including genetic diabetes, MODY, LADA, or diabetes secondary to medications or surgery.
    • Treatment limit: Member will not exceed a one-time 14-day treatment course using the specified dosing schedule.One-time 14-day course

      Days 1-4: 65, 125, 250, and 500 mcg/m2; days 5-14: 1,030 mcg/m2.

    Delay the Decline in Endogenous Insulin Production in Stage 3 Type 1 Diabetes

    Authorization of 12 months may be granted when all criteria are met.

    Recently diagnosed Stage 3 type 1 diabetes criteria

    • Age: Member is 8 to 17 years of age.8 to 17 years
    • Autoantibodies: Member is positive for one or more pancreatic islet cell autoantibodies.At least 1

      Eligible antibodies include GAD, IAA, IA-2A, ZnT8A, and ICA.

    • C-peptide: Member has a peak stimulated C-peptide of at least 0.2 pmol/mL on a mixed meal tolerance test or an appropriate alternative method.At least 0.2 pmol/mL

    Tzield is not effective as a disease-modifying therapy for non-autoimmune dysglycemic conditions.

    Indications other than the specified FDA-approved indications are considered experimental/investigational and are not medically necessary under this policy.

    Use of Tzield outside the specified FDA-approved indications—delaying onset of Stage 3 type 1 diabetes in qualifying Stage 2 disease or delaying decline in endogenous insulin production in qualifying recently diagnosed Stage 3 disease—is not medically necessary.

    Clinical Thresholds and Diagnostic Requirements

    Stage 2 age
    Applicable stageStage 2 type 1 diabetes
    Age requirement1 to less than 45 years
    Coverage purposeDelay the onset of Stage 3 type 1 diabetes
    Stage 2 pancreatic islet autoantibodies
    Minimum numberTwo or more pancreatic islet cell autoantibodies
    ConfirmationConfirmed on two separate occasions
    Eligible examplesGAD, IAA, IA-2A, ZnT8A, or ICA

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization and Endocrinology Requirement

    Prior authorization is required for teplizumab-mzwv (Tzield). Submit indication-specific clinical documentation with the request, and ensure the medication is prescribed by or in consultation with an endocrinologist.

    • Stage 2 indication: authorization may be granted for 1 month to delay onset of Stage 3 type 1 diabetes.
    • Stage 3 indication: authorization may be granted for 12 months to delay decline in endogenous insulin production.
    • The policy is approved but should not be implemented until 12/31/2026.
    Documentation Required

    Stage 2 Documentation Required

    For requests to delay Stage 3 type 1 diabetes in a member with Stage 2 disease, submit documentation establishing the required autoantibody findings and recent dysglycemia.

    • Document positivity for two or more pancreatic islet cell autoantibodies on two separate occasions: GAD, IAA, IA-2A, ZnT8A, or ICA.

    Policy and Therapy Overview

    Teplizumab-mzwv (Tzield) is used to delay progression of type 1 diabetes at specified stages of disease. This policy addresses delaying the onset of Stage 3 type 1 diabetes in adults and pediatric patients at least 1 year of age with Stage 2 disease, and delaying decline in endogenous insulin production in pediatric patients 8 to 17 years of age with recently diagnosed Stage 3 disease. Evidence of safety and effectiveness is limited in patients aged 45 years and older with Stage 2 type 1 diabetes.

    Key Clinical Definitions

    Pancreatic islet cell autoantibodies
    DefinitionAutoantibodies directed against pancreatic islet antigens
    Eligible antibodiesGAD, IAA, IA-2A, ZnT8A, and ICA
    Policy relevanceUsed to establish qualifying Stage 2 or Stage 3 type 1 diabetes criteria
    Stage 2 type 1 diabetes
    AutoantibodiesTwo or more pancreatic islet cell autoantibodies confirmed on two separate occasions
    DysglycemiaQualifying dysglycemia confirmed within the past 2 months
    Clinical status

    Initial Treatment Authorization

    Initial Therapy for Stage 2 Type 1 Diabetes

    Initial Stage 2 therapy may be authorized for 1 month when all criteria are met.

    Initial Stage 2 course

    • Age: Member is 1 to less than 45 years of age.1 to less than 45 years
    • Autoantibodies: Member is positive for two or more pancreatic islet cell autoantibodies on two separate occasions.At least 2 on 2 separate occasions

      Eligible antibodies include GAD, IAA, IA-2A, ZnT8A, and ICA.

    • Dysglycemia

    Subsequent Treatment Course

    Subsequent Stage 3 Treatment Course

    A second course may be authorized when the Stage 3 criteria remain satisfied and the treatment-course limit is observed.

    Second Stage 3 course

    • Course timing and limit: The second 12-day treatment course is administered 6 months after the first, and the member does not exceed two total treatment courses.6 months after first course; maximum 2 courses

    Treatment Duration and Course Limits

    Tzield quantity limit for Stage 2
    DrugTzield (teplizumab-mzwv)
    Treatment courseOne-time 14-day treatment course
    Applicable treatmentStage 2 treatment to delay onset of Stage 3 type 1 diabetes
    Tzield quantity limit for Stage 3
    DrugTzield (teplizumab-mzwv)
    Maximum treatmentTwo 12-day treatment courses
    Timing of second courseAdministered 6 months after the first course
    Policy Summary
    Payerblue cross blue shield - tennessee
    PolicyTeplizumab-mzwv (Tzield) Coverage Policy
    Policy CodePolicy ID_CHS_56782026_1026
    Change TypeNo material clinical or coverage changes
    Effective DateDecember 31, 2026
    Next Review DateN/A
    Key ActionSubmit indication-specific clinical documentation and ensure Tzield is prescribed by or in consultation with an endocrinologist.
    SourceLink
    On This Page
    Covered Indications and Policy LimitsClinical Thresholds and Diagnostic RequirementsAuthorization, Documentation, and Denial RisksPolicy and Therapy OverviewKey Clinical DefinitionsInitial Treatment AuthorizationSubsequent Treatment CourseTreatment Duration and Course Limits

    Appropriate alternatives may include an oral glucose tolerance test or fasting C-peptide.

  1. Recent diagnosis: Stage 3 type 1 diabetes was diagnosed within the past 6 weeks and confirmed by at least one qualifying glucose or A1C criterion.Within 6 weeks

    Qualifying criteria include A1C at least 6.5%, fasting blood glucose at least 126 mg/dL, 2-hour postprandial glucose at least 200 mg/dL during oral glucose tolerance testing, or random plasma glucose at least 200 mg/dL with classic symptoms of hyperglycemia or hyperglycemic crisis.

  2. Timely administration: Provider attests that treatment will be administered as soon as possible following diagnosis and no later than 8 weeks from diagnosis.No later than 8 weeks from diagnosis
  3. Treatment limit: Member will not exceed two 12-day treatment courses, with the second course administered 6 months after the first.Maximum 2 courses; second course 6 months after first

    Days 1-2: 106 and 425 mcg/m2; days 3-12: 850 mcg/m2.

  4. Fasting blood glucose for dysglycemia
    TestFasting blood glucose
    Qualifying range100 to 125 mg/dL
    SI equivalent5.6 to 6.9 mmol/L
    2-hour postprandial plasma glucose for dysglycemia
    Test2-hour postprandial plasma glucose
    Lower thresholdAt least 140 mg/dL (7.8 mmol/L)
    Upper thresholdLess than 200 mg/dL (11.1 mmol/L)
    A1C for dysglycemia
    TestA1C
    Qualifying rangeAt least 5.7% and less than 6.5% (39-47 mmol/mol)
    Alternative criterionAt least a 10% increase in A1C
    Stage 3 age
    Applicable stageRecently diagnosed Stage 3 type 1 diabetes
    Age range8 to 17 years
    Treatment purposeDelay the decline in endogenous insulin production
    Peak stimulated C-peptide
    TestPeak stimulated C-peptide
    Qualifying thresholdAt least 0.2 pmol/mL
    Testing methodMixed meal tolerance test or an appropriate alternative method
    Stage 3 diagnosis timing
    DiagnosisStage 3 type 1 diabetes
    Timing requirementRecently diagnosed within the past 6 weeks
    ConfirmationMust be confirmed by at least one qualifying glucose or A1C criterion
    A1C for Stage 3 diabetes
    TestA1C
    Qualifying thresholdAt least 6.5%
    SI equivalentAt least 48 mmol/mol
    Fasting blood glucose for Stage 3 diabetes
    TestFasting blood glucose
    Qualifying thresholdAt least 126 mg/dL
    SI equivalentAt least 7.0 mmol/L
    2-hour postprandial plasma glucose for Stage 3 diabetes
    Test2-hour postprandial plasma glucose
    Qualifying thresholdAt least 200 mg/dL (at least 11.1 mmol/L)
    Testing contextDuring oral glucose tolerance testing
    Random plasma glucose for Stage 3 diabetes
    TestRandom plasma glucose
    Qualifying thresholdAt least 200 mg/dL (at least 11.1 mmol/L)
    Required clinical contextClassic symptoms of hyperglycemia or hyperglycemic crisis
  5. Submit chart notes or laboratory results documenting dysglycemia within the past 2 months.
  6. Acceptable dysglycemia includes fasting glucose 100–125 mg/dL, 2-hour postprandial glucose at least 140 and less than 200 mg/dL, A1C at least 5.7% and less than 6.5%, or at least a 10% increase in A1C.
  7. Documentation Required

    Stage 3 Documentation Required

    For requests to delay decline in endogenous insulin production in recently diagnosed Stage 3 type 1 diabetes, submit documentation supporting autoimmunity, preserved endogenous insulin production, and the recent diagnosis.

    • Document positivity for one or more pancreatic islet cell autoantibodies: GAD, IAA, IA-2A, ZnT8A, or ICA.
    • Submit a peak stimulated C-peptide of at least 0.2 pmol/mL on a mixed-meal tolerance test, or an appropriate alternative such as an OGTT or fasting C-peptide.
    • Submit chart notes or laboratory results documenting recently diagnosed Stage 3 type 1 diabetes, including qualifying diagnostic results.
    • Diagnosis must be within the past 6 weeks, and the provider must attest that treatment will begin as soon as possible and no later than 8 weeks after diagnosis.
    Denial Risk

    Unapproved or Non-Autoimmune Indication

    Tzield is not effective as a disease-modifying therapy for non-autoimmune dysglycemic conditions. Requests for all other indications, including unapproved or non-autoimmune indications, are considered experimental/investigational and not medically necessary.

    • There is limited evidence of safety and effectiveness in patients aged 45 years and older with Stage 2 type 1 diabetes.
    • Do not submit requests for non-autoimmune dysglycemic conditions as covered indications.
    Denial Risk

    Stage 2 Criteria Not Met

    A Stage 2 request may be denied when any required coverage criterion is not met or cannot be documented.

    • Member is younger than 1 year or 45 years of age or older.
    • Fewer than two qualifying pancreatic islet cell autoantibodies are documented, or positivity is not established on two separate occasions.
    • Required dysglycemia within the past 2 months is absent or does not meet an accepted threshold.
    • Member has symptoms associated with type 1 diabetes, such as increased urination, excessive thirst, or weight loss.
    • Member has type 2 diabetes or another form of diabetes, including genetic diabetes, MODY, LADA, or diabetes secondary to medication or surgery.
    • The requested therapy exceeds the one-time 14-day treatment course or does not follow the required dosing schedule.
    Denial Risk

    Stage 3 Criteria Not Met

    A Stage 3 request may be denied when any required coverage criterion is not met or cannot be documented.

    • Member is younger than 8 or older than 17 years of age.
    • Fewer than one qualifying pancreatic islet cell autoantibody is documented.
    • Peak stimulated C-peptide is below 0.2 pmol/mL or the required test result is not provided.
    • Stage 3 type 1 diabetes was not recently diagnosed within the past 6 weeks, or qualifying diagnostic evidence is absent.
    • The provider does not attest that treatment will be administered as soon as possible and no later than 8 weeks after diagnosis.
    • The requested therapy exceeds two 12-day treatment courses, or the second course is not scheduled 6 months after the first, or the required dosing schedule is not followed.
    Without symptoms associated with type 1 diabetes
    Stage 3 type 1 diabetes
    DefinitionRecently diagnosed Stage 3 type 1 diabetes
    Establishing evidenceQualifying hyperglycemia by A1C, fasting glucose, oral glucose tolerance testing, or random glucose
    Random glucose conditionRandom glucose criterion requires classic symptoms of hyperglycemia or hyperglycemic crisis
    Fasting glucose: Fasting blood glucose is 100 to 125 mg/dL (5.6 to 6.9 mmol/L).100 to 125 mg/dL
  8. Postprandial glucose: Two-hour postprandial plasma glucose is at least 140 mg/dL and less than 200 mg/dL (7.8 to 11.1 mmol/L).At least 140 and less than 200 mg/dL
  9. A1C is at least 5.7% and less than 6.5% (39-47 mmol/mol), or has increased by at least 10%.At least 5.7% and less than 6.5%, or at least 10% increase
  10. Clinical status: Member does not have symptoms associated with type 1 diabetes and does not have type 2 diabetes or another form of diabetes, including genetic diabetes, MODY, LADA, or diabetes secondary to medications or surgery.
  11. Treatment limit: Member will not exceed a one-time 14-day treatment course using the specified dosing schedule.One-time 14-day course

    Days 1-4: 65, 125, 250, and 500 mcg/m2; days 5-14: 1,030 mcg/m2.

  12. Initial Therapy for Recently Diagnosed Stage 3 Type 1 Diabetes

    Initial Stage 3 therapy may be authorized for 12 months when all criteria are met.

    Initial Stage 3 course

    • Age: Member is 8 to 17 years of age.8 to 17 years
    • Autoantibodies: Member is positive for one or more pancreatic islet cell autoantibodies.At least 1

      Eligible antibodies include GAD, IAA, IA-2A, ZnT8A, and ICA.

    • C-peptide: Member has a peak stimulated C-peptide of at least 0.2 pmol/mL on a mixed meal tolerance test or an appropriate alternative method.At least 0.2 pmol/mL

      Appropriate alternatives may include an oral glucose tolerance test or fasting C-peptide.

    • Recent diagnosis: Stage 3 type 1 diabetes was diagnosed within the past 6 weeks and confirmed by at least one qualifying glucose or A1C criterion.Within 6 weeks

      Qualifying criteria include A1C at least 6.5%, fasting blood glucose at least 126 mg/dL, 2-hour postprandial glucose at least 200 mg/dL during oral glucose tolerance testing, or random plasma glucose at least 200 mg/dL with classic symptoms of hyperglycemia or hyperglycemic crisis.

    • Timely administration: Provider attests that treatment will be administered as soon as possible following diagnosis and no later than 8 weeks from diagnosis.No later than 8 weeks from diagnosis
    • Treatment limit: Member will not exceed two 12-day treatment courses, with the second course administered 6 months after the first.Maximum 2 courses; second course 6 months after first

      Days 1-2: 106 and 425 mcg/m2; days 3-12: 850 mcg/m2.